Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Thematic (Sector/Industry)

<a href="https://www.smartkarma.com/entities/21112" target="_blank" data-smartkarma-citation="entities:21112:1">Galapagos NV (GLPG NA)</a> seems to have got some investor attention after the successful results of <a href="https://www.smartkarma.com/entities/7410" target="_blank" data-smartkarma-citation="entities:7410:1">Celgene Corp (CELG US)</a> anti-inflammatory product candidate for the treatment of Crohn's disease. Galapagos' filgotinib is being developed in partnership with <a href="https://www.smartkarma.com/entities/973" target="_blank" data-smartkarma-citation="entities:973:1">Gilead Sciences Inc (GILD US)</a> and showed 48% remission and 67% clinical response in Crohn's disease. A phase 3 trial of the drug will start soon. Our sentiment on Galapagos stock: neutral. <a href="https://www.smartkarma.com/entities/8669" target="_blank" data-smartkarma-citation="entities:8669:1">Atara Biotherapeutics Inc (ATRA US)</a> received PRIME…

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product candidate for the treatment of Crohn's disease. Galapagos' filgotinib is being developed in partnership with Gilead Sciences Inc (GILD US) and showed 48% remission and 67% clinical response in Crohn's disease. A phase 3 trial of the drug will start soon. Our sentiment on Galapagos stock: neutral. Atara Biotherapeutics Inc (ATRA US) received PRIME…

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate and 67% clinical response rate). The company will also present data from an on-going phase 2 study of ozanimod, S1P1 modulator at upcoming scientific conferences, including the American College of Gastroenterology annual meeting. Our sentiment: BullishTetraphase Pharmaceuticals (NASDAQ: TTPH) started a phase 3 trial of its antibiotic candidate…

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate and 67% clinical response rate). The company will also present data from an on-going phase 2 study of ozanimod, S1P1 modulator at upcoming scientific conferences, including the American College of Gastroenterology annual meeting. Our sentiment: BullishTetraphase Pharmaceuticals (NASDAQ: TTPH) started a phase 3 trial of its antibiotic candidate…

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Asean-focused. Ex-Head of Thai Research

Athaporn Arayasantiparb, CFA

Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues. Both candidates seem to be having a tough time yo:<ul><li>
Wikileaks vs Hillary: Julian Assange of Wikileaks threatened to spill the beans on Hillary saying that she sat on the board of France's cement maker Lafarge, which operates in certain areas of Iraq and paid taxes to ISIS. Gee whiz! The French should be more angry about this than Americans. Terrorists…</li></ul>

Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues. Both candidates seem to be having a tough time yo:
Wikileaks vs Hillary: Julian Assange of Wikileaks threatened to spill the beans on Hillary saying that she sat on the board of France's cement maker Lafarge, which operates in certain areas of Iraq and paid taxes to ISIS. Gee whiz! The French should be more angry about this than Americans. Terrorists…

Strike 2 in St Louis: Trump's Town Hall Trap

Public Relations and Social Media Manager, Dechert LLP

Peggy Heffner

Public Relations and Social Media Manager

Dechert is a global specialist law firm

Dechert LLP

Dechert is a global specialist law firm.
Focused on sectors with the greatest complexities, legal intricacies and highest regulatory demands, we excel in delivering practical commercial judgment and deep legal expertise for high-stakes matters.

Our work is widely recognized. We have 20 standout practices noted by Chambers Global, including global-wide rankings for arbitration, corporate investigations, anti-corruption, investment funds and life sciences. Named Antitrust Team of the Year, Chambers USA commends our “accomplished group” as “routinely sought after to handle some of the most significant litigation and transactions in the antitrust world.” 

In an increasingly challenging environment, clients look to us to serve them in ways that are faster, sharper and leaner without compromising excellence. We developed a first-of-its kind legal project management department, which uses technology, people and processes to drive efficiency and deliver value for our clients.

We are innovators. Dechert ranked #7 in the Financial Times’ Top North American Innovative Law Firms. Financial Times also recognizes us among the Top European Innovative Law Firms and highly commends World Compass, our marketing compliance service, which offers investment firms advice in more than 100 jurisdictions.

Event-Driven

Fast Facts<ul><li>In the first three quarters of 2016, there were 24 significant merger investigations, which is on pace to challenge the record of 37 set in CY2015. </li><li>Significant merger investigations through Q3 2016 lasted 9.7 months on average—on par with CY2015, but more than one-third longer than from 2011 to 2013. </li><li>The antitrust agencies filed three complaints in the third quarter for a total of five complaints YTD, also on pace to challenge the record level of CY2015 when seven complaints were filed.</li><li>Scheduling orders related to the complaints filed in 2016 indicate that antitrust merger litigation is taking even longer with 147 days between complaint and the start of trial and 27 days for trial, up 47% and 125%, respectively, from cases filed in CY2015.</li></ul>

 Fast FactsIn the first three quarters of 2016, there were 24 significant merger investigations, which is on pace to challenge the record of 37 set in CY2015. Significant merger investigations through Q3 2016 lasted 9.7 months on average—on par with CY2015, but more than one-third longer than from 2011 to 2013. The antitrust agencies filed three complaints in the third quarter for a total of five complaints YTD, also on pace to challenge the record level of CY2015 when seven complaints were filed.Scheduling orders related to the complaints filed in 2016 indicate that antitrust merger litigation is taking even longer with 147 days between complaint and the start of trial and 27 days for trial, up 47% and 125%, respectively, from cases filed in CY2015.

No Let Up in Antitrust Merger Investigation or the Duration of Merger Investigations

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook.<ul><li class="p1">We anticipate high-single-digit growth for Allergan through 2020 thanks to defensibility of the aesthetics business, strong intellectual property protection on most major products, and new innovative product launches, which includes pipeline opportunities to support Allergan's aesthetics, dry-eye, glaucoma, depression, and gastroenterology franchises.</li><li class="p1">Our forecasts for Allergan match consensus estimates, but we think the stock price doesn't reflect the above-average growth rate and profitability of this wide-moat firm.</li><li class="p1">Unlike lower quality specialty pharma peers, Allergan has low financial leverage, patent protection on key products well beyond 2020, and an innovative pipeline that supports future prescription growth and pricing power.</li><li class="p1">Additionally, Allergan possesses a disciplined management team and has not been overly reliant on price increases for growth, from our perspective.</li></ul>

Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook.We anticipate high-single-digit growth for Allergan through 2020 thanks to defensibility of the aesthetics business, strong intellectual property protection on most major products, and new innovative product launches, which includes pipeline opportunities to support Allergan's aesthetics, dry-eye, glaucoma, depression, and gastroenterology franchises.Our forecasts for Allergan match consensus estimates, but we think the stock price doesn't reflect the above-average growth rate and profitability of this wide-moat firm.Unlike lower quality specialty pharma peers, Allergan has low financial leverage, patent protection on key products well beyond 2020, and an innovative pipeline that supports future prescription growth and pricing power.Additionally, Allergan possesses a disciplined management team and has not been overly reliant on price increases for growth, from our perspective.

Allergan's Wide Moat Supports Industry-Leading Growth and Profit

United States

Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mylan NV (MYL US)

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...

Dr. Bhavneesh Sharma, MD, MBA

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...

Dr. Bhavneesh Sharma, MD, MBA

Strike 2 in St Louis: Trump's Town Hall Trap

Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues....

Athaporn Arayasantiparb, CFA

No Let Up in Antitrust Merger Investigation or the Duration of Merger Investigations

Fast Facts In the first three quarters of 2016, there were 24 significant merger investigations, which is on pace to challenge the record of 37...

Dechert LLP

Allergan's Wide Moat Supports Industry-Leading Growth and Profit

Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook. We anticipate high-single-digit growth for...

Morningstar, Inc.

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)